Q4) compared with normal values (Q1-Q3) in B with median overall survival of 28.3 vs 38.1 months (HR¼2.0, 95%CI:1.13-3.68; p<0.018). We then confirmed a numerical increase in monocytes and decrease in T-cell lymphocytes at P in the validation cohort and validated both conditions in B with worse survival for high monocytes (HR ¼ 2.2, 95%CI: 1.06-4.23; p< 0.03) and low T-cell lymphocytes (HR ¼ 3.9, 95%CI: 1.95-7.93; <0.001).Conclusions: Prostate cancer progression is associated with changes in peripheral blood that compromise activation of immune-regulatory components, including the expansion of monocytes. These findings could offer biomarker and therapeutic opportunities to reverse resistance to enzalutamide.Clinical trial identification: NCT02288936.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.